164 related articles for article (PubMed ID: 36119502)
1. [
Truckenmueller P; Graef J; Scheel M; Vajkoczy P; Capper D; Kaul D; Furth C; Amthauer H; Brenner W; Onken JS
Front Oncol; 2022; 12():980058. PubMed ID: 36119502
[TBL] [Abstract][Full Text] [Related]
2. Baseline [
Groener D; Schneider S; Baumgarten J; Happel C; Klimek K; Mader N; Nguyen Ngoc C; Wichert J; Mandel P; Tselis N; Grünwald F; Sabet A
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672421
[TBL] [Abstract][Full Text] [Related]
3. Impact of [
Groener D; Wichert J; Adams M; Mader N; Klimek K; Nguyen Ngoc C; Baumgarten J; Happel C; Mandel P; Chun FKH; Tselis N; Grünwald F; Sabet A
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568694
[TBL] [Abstract][Full Text] [Related]
4. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
5. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
6. Value of Combined PET Imaging with [
Khreish F; Ribbat K; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Schreckenberger M; Ezziddin S; Rosar F
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439287
[TBL] [Abstract][Full Text] [Related]
7. Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo.
Kumar A; ArunRaj ST; Bhullar K; Haresh KP; Gupta S; Ballal S; Yadav M; Singh M; Damle NA; Garg A; Tripathi M; Bal C
Neuroradiology; 2022 May; 64(5):969-979. PubMed ID: 34648046
[TBL] [Abstract][Full Text] [Related]
8. PET/CT using
Liu D; Cheng G; Ma X; Wang S; Zhao X; Zhang W; Yang W; Wang J
J Neuroimaging; 2021 Jul; 31(4):733-742. PubMed ID: 34021667
[TBL] [Abstract][Full Text] [Related]
9. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions.
Wang J; Zang J; Wang H; Liu Q; Li F; Lin Y; Huo L; Jacobson O; Niu G; Fan X; Zhu Z; Chen X
Clin Nucl Med; 2019 Jun; 44(6):431-438. PubMed ID: 30985422
[TBL] [Abstract][Full Text] [Related]
10. [
Peters SMB; Hofferber R; Privé BM; de Bakker M; Gotthardt M; Janssen M; de Lange F; Muselaers CHJ; Mehra N; Witjes JA; Costa PF; Nagarajah J; Konijnenberg MW; Jentzen W
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1101-1112. PubMed ID: 34623453
[TBL] [Abstract][Full Text] [Related]
11. Outcome and safety of rechallenge [
Yordanova A; Linden P; Hauser S; Meisenheimer M; Kürpig S; Feldmann G; Gaertner FC; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1073-1080. PubMed ID: 30474706
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of
Wang G; Zhou M; Zang J; Jiang Y; Chen X; Zhu Z; Chen X
EJNMMI Res; 2022 Aug; 12(1):52. PubMed ID: 35984529
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.
Lückerath K; Wei L; Fendler WP; Evans-Axelsson S; Stuparu AD; Slavik R; Mona CE; Calais J; Rettig M; Reiter RE; Herrmann K; Radu CG; Czernin J; Eiber M
EJNMMI Res; 2018 Oct; 8(1):96. PubMed ID: 30374743
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeling of PSMA-617 with
Imura R; Ozeki AN; Shida N; Kobayashi M; Ida H; Wada Y; Akimitsu N; Kumakura Y
Nucl Med Biol; 2022; 106-107():21-28. PubMed ID: 34998216
[TBL] [Abstract][Full Text] [Related]
15. PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under
Widjaja L; Werner RA; Ross TL; Bengel FM; Derlin T
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208246
[No Abstract] [Full Text] [Related]
16. Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with
Kalshetty A; Menon B; Rakshit S; Bhattacharjee A; Basu S
J Nucl Med Technol; 2021 Sep; 49(3):235-240. PubMed ID: 34244223
[TBL] [Abstract][Full Text] [Related]
17. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
18. In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2
Prasad V; Huang K; Prasad S; Makowski MR; Czech N; Brenner W
Front Oncol; 2021; 11():578093. PubMed ID: 33816225
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of [
Rosar F; Krause J; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Ezziddin S; Khreish F
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34069003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]